(Q35748487)

10 August 2017

title

Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients (English)

1 reference

10 August 2017

7

Marc Ladanyi

1 reference

10 August 2017

8

Shunichi Yamashita

1 reference

10 August 2017

author name string

Julio C Ricarte-Filho

1

1 reference

10 August 2017

Michiko Matsuse

2

1 reference

10 August 2017

Christopher Lau

3

1 reference

10 August 2017

Mabel Ryder

4

1 reference

10 August 2017

Eijun Nishihara

5

1 reference

10 August 2017

Ronald A Ghossein

6

1 reference

10 August 2017

Norisato Mitsutake

9

1 reference

10 August 2017

James A Fagin

10

1 reference

10 August 2017

language of work or name

English

0 references

publication date

24 August 2011

1 reference

International Journal of Cancer

10 August 2017

published in

1 reference

10 August 2017

volume

130

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

2215-7; author reply 2217-8

1 reference

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

A phase II study of gefitinib in patients with advanced thyroid cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276702

25 September 2018

Identifiers

DOI

10.1002/IJC.26267

1 reference

10 August 2017

1 reference

10 August 2017

1 reference